Many cell and gene therapy companies are initiating new programs and collaborations with the start of the new year.
As we head into 2022, many cell and gene therapy companies are growing and collaborating to develop new innovative therapies while other pharmaceutical companies are establishing cell and gene therapy divisions of their own. We have compiled the latest company news in gene and cell therapies, including partnerships, pipeline updates, and more.
Selecta is combining their ImmTOR platform with Ginkgo’s cell programming platform to develop safer and more effective gene therapy viral capsids. The collaboration aims to create capsids with improved transduction, reduced immunogenicity, and enhanced tissue tropism. Selecta will conduct trials to evaluate the capsids, which will be engineered by Ginkgo.
Bayer is collaborating with Mammoth to use their CRISPR platform to develop in vivo gene-editing therapies, expanding the company’s new cell and gene platform. The collaboration will initially focus on liver-targeted diseases.
Carisma’s engineered macrophage technology and Moderna’s mRNA and lipid nanoparticle will be combined to create in vivo chimeric antigen receptor (CAR)-macrophage therapeutics for various oncologic targets. Carisma will discover and optimize candidates while Modern will develop and commercialize candidates.
Four clinical trial sites for the Acclaim-1 phase 1/2 trial (NCT04486833) will soon open to evaluate quaratusugeneozeplasmid (Reqorsa), Genprex’sImmunogene therapy, with AstraZeneca’s osimertinib (Tagrisso) for the potential treatment of non-small cell lung cancer. Additional sites will later open for the phase 2 portion of the study.
Novavita is a gene therapy company with preclinical studies in rare liver and metabolic disease in vivo gene therapies. The acquisition will bolster Castle Creek’s existing ex vivo gene therapy strategies and current programs in skin and connective tissue disorders.
Warden Bio is developing AAV gene therapies for glycogen storage disorders, including Pompe disease. Kriya’s acquisition of Warden will be the foundation of their rare disease division. The company is also currently developing gene therapies in ophthalmology, oncology, and chronic diseases.
The new agreement expands the companies’ existing research collaboration to identify and develop a gene therapy candidate for hemophilia A. The expanded agreement will allow Novo Nordisk to license 2seventy bio’s mRNA megaTAL technology to develop an in vivo gene editing therapy for the same indication.
Pfizer and Beam are collaborating to use Beam’s mRNA and lipid nanoparticle in vivo delivery technologies to develop gene base editing programs for rare liver, muscle, and central nervous system genetic diseases. Beam will research and develop candidates which Pfizer will later develop and commercialize.
Bristol Myers Squibb(BMS) is collaborating with Century Therapeutics for the use of their iPSC-derived, natural killer and T cell allogeneic cell therapies to develop therapies for oncologic indications, initially acute myeloid leukemia and multiple myeloma.
BMS also announced an expanded collaboration with ArsenalBio to initiate a new program to develop next-generation T-cell therapies for solid tumors on the same day. BMS is responsible for developing and commercializing candidates developed by their partners from both collaborations.